The Econo Miss

Since the Vioxx scandal, drug companies have not been favourites with investors. Despite their efforts in research and development, one drug after another is quietly scrapped. Pfizer, the struggling US pharmaceutical giant discontinued its inhaled insulin drug, Exubera after it failed to spark the interest of doctors and patients.

Since the Vioxx scandal, drug companies have not been favourites with investors. Despite their efforts in research and development, one drug after another is quietly scrapped. Pfizer, the struggling US pharmaceutical giant discontinued its inhaled insulin drug, Exubera after it failed to spark the interest of doctors and patients.
Exubera was thought to be the next big thing; a product that would finally make Pfizer some money after the lost of sales from the rapid expiration of its patented best sellers. The company’s profit fell 11 cents per share. Pfizer is still struggling to substantially increase their profits and offset losses on their patents.
To bring a new drug to the market, it can take global drug companies up to $1 billion. However, producing a drug in India may cost only one fifth of that. Ranbaxy, India’s largest pharmaceutical company is opening a branch of research and development. Most drug companies in India produce only generic drugs and this news from Ranbaxy may pave the way for other pharmaceuticals to begin researching their own drugs. It is hoped that this news will spark the interest of investors. Ranbaxy is already in the mid clinical stages of testing a new anti-malarial drug. It also hopes to research in the areas of oncology, metabolic, and respiratory diseases. Despite the good intentions of Ranbaxy and Pfizer, drug companies are still too risky for many investors and since the Vioxx scandal they are hard to trust.
Crude oil prices will continue to climb; the increasing tensions in the Middle East and China’s economic boom will ensure that. The Bank of America has reported they see defaults not only in housing, but also in the levels of consumer debt. Although some analysts are saying the credit crunch may be good for the long term. While Canada is at a low for unemployment, the US has had a jump of 28,000 new unemployment claims last week.

Total
0
Shares

Comments are closed.

Previous Article

Habs Report: Week 2 had fans up and down

Next Article

Friends don't censor Friends - unless you're Friendster

Related Posts

Europe goes green – well, barely

With its first phase coming to an end, Europe's emissions trading scheme, touted as the best course of action on the road to Kyoto, has proven to put only minimal pressure on Europe's biggest polluters. Edit Kiss, an emissions trading analyst with carbon brokerage firm Vertis Finance in Budapest said, "There was so much over-allocation of permits in this phase that in April 2006, the value of carbon dropped by 60 per cent, and there was no drop in pollution.
Read More

Battle of the briefcases

After six days of debating and deliberating, Université Laval has come out on top in the 31st annual John Molson School of Business MBA International Case Competition, winning $10,000 in cash and the Concordia Cup.